13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001778253
Total reported value
$928.2M
$928.2M
121 檔
27.2%
As reported in its official Q3 2024 Form 13F filing, Ikarian Capital, LLC's tracked investment portfolio stood at $928.2M with 121 total positions.
In Q3 2024, Ikarian Capital, LLC displayed an active expansion posture, initiating 40 new positions and adding to 17 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 12.97% | — | — | |
| 2 | AMGN | Amgen Inc | Stock-Healthcare | 7.16% | — | +309.51% | |
| 3 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 6.89% | -3.19% | — | |
| 4 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 4.73% | +0.03% | +28.74% | |
| 5 | ANAB | Anaptysbio Inc | Stock-Other | 3.52% | — | — | |
| 6 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 3.04% | — | -27.50% | |
| 7 | CLDX | Celldex Therapeutics Inc | Stock-Other | 2.90% | +0.90% | — | |
| 8 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 2.33% | -0.94% | EXIT | |
| 9 | JANX | Janux Therapeutics Inc | Stock-Other | 2.31% | — | — | |
| 10 | BHVN | Biohaven Ltd. | Stock-Other | 2.27% | +0.92% | — | |
| 11 | VRDN | Viridian Therapeutics Inc | Stock-Other | 2.22% | +0.84% | NEW | |
| 12 | IMVT | Immunovant Inc | Stock-Other | 1.99% | — | +79.90% | |
| 13 | CAPR | Capricor Therapeutics Inc | Stock-Other | 1.91% | +0.31% | — | |
| 14 | RCUS | Arcus Biosciences Inc | Stock-Other | 1.83% | +1.68% | NEW | |
| 15 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 1.80% | — | +102.11% | |
| 16 | ELVN | Enliven Therapeutics Inc | Stock-Other | 1.78% | +0.42% | -14.83% | |
| 17 | CYTK | Cytokinetics Inc | Stock-Healthcare | 1.64% | -6.65% | EXIT | |
| 18 | INSM | Insmed Inc | Stock-Healthcare | 1.58% | -0.06% | EXIT | |
| 19 | NMRA | Neumora Therapeutics Inc | Stock-Other | 1.47% | +0.03% | — | |
| 20 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 1.41% | — | — | |
| 21 | ANRO | Alto Neuroscience Inc | Stock-Other | 1.41% | +0.22% | — | |
| 22 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 1.39% | -0.22% | — | |
| 23 | AVTX | Avalo Therapeutics Inc | Stock-Other | 1.29% | -0.50% | +1672.99% | |
| 24 | SYRE | Spyre Therapeutics Inc | Stock-Other | 1.24% | — | — | |
| 25 | ONC | Beone Medicines Ltd-adr | Stock-Other | 1.16% | — | — | |
| 26 | CPRX | Catalyst Pharmaceuticals Inc | Stock-Healthcare | 1.16% | — | -19.39% | |
| 27 | TECX | Tectonic Therapeutic Inc | Stock-Other | 1.13% | +0.36% | +325.15% | |
| 28 | 2655787D | Blueprint Medicines CORP | Stock-Other | 1.10% | — | — | |
| 29 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 1.01% | -0.86% | -15.50% | |
| 30 | BDTX | Black Diamond Therapeutics I | Stock-Other | 1.00% | — | — | |
| 31 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 0.94% | — | -73.52% | |
| 32 | NRIX | Nurix Therapeutics Inc | Stock-Other | 0.81% | — | -40.98% | |
| 33 | AKRO | Akero Therapeutics Inc | Stock-Other | 0.80% | — | — | |
| 34 | SANA | Sana Biotechnology Inc | Stock-Other | 0.75% | — | +16150.00% | |
| 35 | NUVL | Nuvalent Inc-a | Stock-Other | 0.75% | -0.20% | EXIT | |
| 36 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.71% | — | +19762.07% | |
| 37 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 0.70% | — | — | |
| 38 | RLAY | Relay Therapeutics Inc | Stock-Other | 0.68% | — | — | |
| 39 | LENZ | Lenz Therapeutics Inc | Stock-Other | 0.68% | — | — | |
| 40 | PYXS | Pyxis Oncology Inc | Stock-Other | 0.67% | — | -21.01% | |
| 41 | DYN | Dyne Therapeutics Inc | Stock-Other | 0.67% | — | — | |
| 42 | WVE | Wave Life Sciences Ltd. | Stock-Other | 0.62% | — | -5.36% | |
| 43 | RZLT | Rezolute Inc | Stock-Other | 0.60% | +0.52% | -1.83% | |
| 44 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.59% | — | — | |
| 45 | EOLS | Evolus Inc | Stock-Other | 0.58% | — | — | |
| 46 | ABEO | Abeona Therapeutics Inc | Stock-Other | 0.51% | — | -24.09% | |
| 47 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 0.51% | — | — | |
| 48 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 0.47% | +0.06% | +15.92% | |
| 49 | ✓ | Acelyrin Inc | Stock-Other | 0.47% | — | -54.10% | |
| 50 | HELP | Cybin Inc | Stock-Other | 0.46% | +0.04% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | VRTX | Vertex Pharmaceuticals Inc | +13% | NEW | New buy |
| 2 | XBI | Ss Spdr S&p Biotech ETF | +6.9% | NEW | New buy |
| 3 | ANAB | Anaptysbio Inc | +3.5% | NEW | New buy |
| 4 | AMGN | Amgen Inc | +3.4% | +309.51% | Add |
| 5 | CLDX | Celldex Therapeutics Inc | +2.9% | NEW | New buy |
| 6 | JANX | Janux Therapeutics Inc | +2.3% | NEW | New buy |
| 7 | BHVN | Biohaven Ltd. | +2.3% | NEW | New buy |
| 8 | VRDN | Viridian Therapeutics Inc | +2.2% | +18373.92% | Add |
| 9 | CAPR | Capricor Therapeutics Inc | +1.9% | NEW | New buy |
| 10 | NMRA | Neumora Therapeutics Inc | +1.5% | NEW | New buy |
| 11 | APLSUSD | Apellis Pharmaceuticals Inc | +1.4% | NEW | New buy |
| 12 | ANRO | Alto Neuroscience Inc | +1.4% | NEW | New buy |
| 13 | RARE | Ultragenyx Pharmaceutical In | +1.4% | NEW | New buy |
| 14 | SYRE | Spyre Therapeutics Inc | +1.2% | NEW | New buy |
| 15 | ONC | Beone Medicines Ltd-adr | +1.2% | NEW | New buy |
| 16 | RCUS | Arcus Biosciences Inc | +1.2% | +491.52% | Add |
| 17 | 2655787D | Blueprint Medicines CORP | +1.1% | NEW | New buy |
| 18 | AVTX | Avalo Therapeutics Inc | +1.1% | +1672.99% | Add |
| 19 | BDTX | Black Diamond Therapeutics I | +1% | NEW | New buy |
| 20 | TECX | Tectonic Therapeutic Inc | +0.8% | +325.15% | Add |
| 21 | AKRO | Akero Therapeutics Inc | +0.8% | NEW | New buy |
| 22 | SANA | Sana Biotechnology Inc | +0.7% | +16150.00% | Add |
| 23 | MDGL | Madrigal Pharmaceuticals Inc | +0.7% | NEW | New buy |
| 24 | GPCR | Structure Therapeutics Inc | +0.7% | +19762.07% | Add |
| 25 | RLAY | Relay Therapeutics Inc | +0.7% | NEW | New buy |
| 26 | DYN | Dyne Therapeutics Inc | +0.7% | NEW | New buy |
| 27 | EOLS | Evolus Inc | +0.6% | NEW | New buy |
| 28 | INSM | Insmed Inc | +0.5% | +188.80% | Add |
| 29 | HELP | Cybin Inc | +0.5% | NEW | New buy |
| 30 | GALT | Galectin Therapeutics Inc | +0.4% | NEW | New buy |
| 31 | LXEO | Lexeo Therapeutics Inc | +0.3% | NEW | New buy |
| 32 | MLYS | Mineralys Therapeutics Inc | +0.3% | NEW | New buy |
| 33 | SLDB | Solid Biosciences Inc | +0.3% | NEW | New buy |
| 34 | FULC | Fulcrum Therapeutics Inc | +0.3% | NEW | New buy |
| 35 | ✓ | Reneo Pharmaceuticals Inc | +0.2% | NEW | New buy |
| 36 | GLUE | Monte Rosa Therapeutics Inc | +0.2% | NEW | New buy |
| 37 | SWTXUSD | Springworks Therapeutics Inc | +0.2% | NEW | New buy |
| 38 | CRVS | Corvus Pharmaceuticals Inc | +0.2% | NEW | New buy |
| 39 | OLMA | Olema Pharmaceuticals Inc | +0.2% | NEW | New buy |
| 40 | CATX | Perspective Therapeutics Inc | +0.1% | NEW | New buy |
| 41 | ✓ | +0.1% | NEW | New buy | |
| 42 | ALNY | Alnylam Pharmaceuticals Inc | +0.1% | +191.37% | Add |
| 43 | ✓ | Verve Therapeutics Inc | +0.1% | NEW | New buy |
| 44 | BMEA | Biomea Fusion Inc | +0.1% | NEW | New buy |
| 45 | NAMS | NewAmsterdam Pharma Company N.V. | +0.1% | NEW | New buy |
| 46 | PRTA | Prothena Corporation plc | +0.1% | NEW | New buy |
| 47 | APGE | Apogee Therapeutics Inc | 0% | NEW | New buy |
| 48 | ✓ | 0% | NEW | New buy | |
| 49 | FDMT | 4d Molecular Therapeutics In | — | NEW | New buy |
| 50 | CTMX | Cytomx Therapeutics Inc | — | — | Unchanged |
According to official SEC Form 13F filings, Ikarian Capital, LLC reported a total U.S. public equity portfolio value of $928.2M across 121 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including VRTX, AMGN, XBI) accounted for 27.2% of total reported equity market value during Q3 2024.
Top New Position Initiated
VRTX
市值: $93.0M
Top Position Liquidated / Trimmed
VKTX
前期市值: $7.3M
During Q3 2024, Ikarian Capital, LLC's top holdings by market value included VRTX (13.0%)、AMGN (7.2%)、XBI (6.9%). The largest single position, VRTX, represented 13.0% of total portfolio value.
In Q3 2024, Ikarian Capital, LLC made 99 total portfolio adjustments, initiating 40 new buys, adding to 17 positions, trimming 28 holdings, and fully liquidating 14 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.